The CHMP has recommended Foundayo (orforglipron), a once-daily oral GLP-1 receptor agonist for weight management and type 2 diabetes in adults. A tablet in this class changes the conversation for regulators, payers and supply chains alike.
What was recommended
EMA’s October 2026 highlights list Foundayo among six new medicines. It is a tablet taken once daily, which distinguishes it from the injectable products that have dominated the class. The Commission decision normally follows within 67 days of the opinion.
Quality considerations for oral peptide-class products
For oral formulations in this therapeutic area, inspectors and assessors tend to look closely at the manufacturing process, the dissolution profile and comparability across batches and sites. Sponsors and contract manufacturers should expect questions on process validation, control strategy and change management once volumes scale up.
Market access questions in Greece
- Indication wording. Reimbursement rarely follows the full label. Payers distinguish between diabetes and weight management, and between patient subgroups.
- Budget impact. A convenient oral option can widen the eligible population, which is exactly what budget impact models are asked to test.
- Comparators. HTA submissions need to position the product against existing injectable therapies and current standard care.
- Supply planning. High demand for a class makes realistic forecasting and shortage-prevention planning part of the launch dossier.
Pharmacovigilance from day one
New products in widely used classes attract early safety scrutiny. A risk management plan, clear signal detection routines and well-prepared educational materials, where required, should be in place before launch.
How PQRA helps
PQRA supports sponsors across marketing authorisation follow-up, Greek pricing and reimbursement dossiers, budget impact modelling and pharmacovigilance set-up, so a centralised opinion becomes a managed national launch.


No responses yet